EP 862

Drug Profile

EP 862

Latest Information Update: 28 Mar 2008

Price : $50

At a glance

  • Originator EPIX Pharmaceuticals
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Thrombosis

Most Recent Events

  • 28 May 2003 No development reported - Preclinical for Magnetic resonance imaging in USA (unspecified route)
  • 29 Mar 2000 Preclinical development for Magnetic resonance imaging in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top